BACKGROUND AND PURPOSE: Artificial agonists may have higher efficacy for receptor activation than the physiological agonist. Until now, such 'superagonism' has rarely been reported for GPCRs. Iperoxo is an extremely potent muscarinic receptor agonist. We hypothesized that iperoxo is a 'superagonist'. EXPERIMENTAL APPROACH: Signalling of iperoxo and newly synthesized structural analogues was compared with that of ACh at label-free M2 muscarinic receptors applying whole cell dynamic mass redistribution, measurement of G-protein activation, evaluation of cell surface agonist binding and computation of operational efficacies. KEY RESULTS: In CHO-hM2 cells, iperoxo significantly exceeds ACh in Gi /Gs signalling competence. In the orthosteric loss-of-function mutant M2 -Y104(3.33) A, the maximum effect of iperoxo is hardly compromised in contrast to ACh. 'Superagonism' is preserved in the physiological cellular context of MRC-5 human lung fibroblasts. Structure-signalling relationships including iperoxo derivatives with either modified positively charged head group or altered tail suggest that 'superagonism' of iperoxo is mechanistically based on parallel activation of the receptor protein via two orthosteric interaction points. CONCLUSION AND IMPLICATIONS: Supraphysiological agonist efficacy at muscarinic M2 ACh receptors is demonstrated for the first time. In addition, a possible underlying molecular mechanism of GPCR 'superagonism' is provided. We suggest that iperoxo-like orthosteric GPCR activation is a new avenue towards a novel class of receptor activators.
BACKGROUND AND PURPOSE: Artificial agonists may have higher efficacy for receptor activation than the physiological agonist. Until now, such 'superagonism' has rarely been reported for GPCRs. Iperoxo is an extremely potent muscarinic receptor agonist. We hypothesized that iperoxo is a 'superagonist'. EXPERIMENTAL APPROACH: Signalling of iperoxo and newly synthesized structural analogues was compared with that of ACh at label-free M2 muscarinic receptors applying whole cell dynamic mass redistribution, measurement of G-protein activation, evaluation of cell surface agonist binding and computation of operational efficacies. KEY RESULTS: In CHO-hM2 cells, iperoxo significantly exceeds ACh in Gi /Gs signalling competence. In the orthosteric loss-of-function mutant M2 -Y104(3.33) A, the maximum effect of iperoxo is hardly compromised in contrast to ACh. 'Superagonism' is preserved in the physiological cellular context of MRC-5 human lung fibroblasts. Structure-signalling relationships including iperoxo derivatives with either modified positively charged head group or altered tail suggest that 'superagonism' of iperoxo is mechanistically based on parallel activation of the receptor protein via two orthosteric interaction points. CONCLUSION AND IMPLICATIONS: Supraphysiological agonist efficacy at muscarinic M2 ACh receptors is demonstrated for the first time. In addition, a possible underlying molecular mechanism of GPCR 'superagonism' is provided. We suggest that iperoxo-like orthosteric GPCR activation is a new avenue towards a novel class of receptor activators.
Authors: Karen J Gregory; Nathan E Hall; Andrew B Tobin; Patrick M Sexton; Arthur Christopoulos Journal: J Biol Chem Date: 2010-01-05 Impact factor: 5.157
Authors: Klaus Mohr; Christian Tränkle; Evi Kostenis; Elisabetta Barocelli; Marco De Amici; Ulrike Holzgrabe Journal: Br J Pharmacol Date: 2010-02-05 Impact factor: 8.739
Authors: Celine Valant; Karen J Gregory; Nathan E Hall; Peter J Scammells; Michael J Lew; Patrick M Sexton; Arthur Christopoulos Journal: J Biol Chem Date: 2008-08-22 Impact factor: 5.157
Authors: Andreas Bock; Brian Chirinda; Fabian Krebs; Regina Messerer; Julia Bätz; Mathias Muth; Clelia Dallanoce; Dominika Klingenthal; Christian Tränkle; Carsten Hoffmann; Marco De Amici; Ulrike Holzgrabe; Evi Kostenis; Klaus Mohr Journal: Nat Chem Biol Date: 2013-11-10 Impact factor: 15.040
Authors: Rhonda L Carter; Laurel A Grisanti; Justine E Yu; Ashley A Repas; Meryl Woodall; Jessica Ibetti; Walter J Koch; Marlene A Jacobson; Douglas G Tilley Journal: Pharmacol Res Perspect Date: 2014-02
Authors: Ramona Schrage; Anna-Lena Schmitz; Evelyn Gaffal; Suvi Annala; Stefan Kehraus; Daniela Wenzel; Katrin M Büllesbach; Tobias Bald; Asuka Inoue; Yuji Shinjo; Ségolène Galandrin; Naveen Shridhar; Michael Hesse; Manuel Grundmann; Nicole Merten; Thomas H Charpentier; Matthew Martz; Adrian J Butcher; Tanja Slodczyk; Sylvain Armando; Maike Effern; Yoon Namkung; Laura Jenkins; Velten Horn; Anne Stößel; Harald Dargatz; Daniel Tietze; Diana Imhof; Céline Galés; Christel Drewke; Christa E Müller; Michael Hölzel; Graeme Milligan; Andrew B Tobin; Jesús Gomeza; Henrik G Dohlman; John Sondek; T Kendall Harden; Michel Bouvier; Stéphane A Laporte; Junken Aoki; Bernd K Fleischmann; Klaus Mohr; Gabriele M König; Thomas Tüting; Evi Kostenis Journal: Nat Commun Date: 2015-12-14 Impact factor: 14.919
Authors: Regina Messerer; Clelia Dallanoce; Carlo Matera; Sarah Wehle; Lisa Flammini; Brian Chirinda; Andreas Bock; Matthias Irmen; Christian Tränkle; Elisabetta Barocelli; Michael Decker; Christoph Sotriffer; Marco De Amici; Ulrike Holzgrabe Journal: Medchemcomm Date: 2017-04-27 Impact factor: 3.597
Authors: Almudena Barbero-Castillo; Fabio Riefolo; Carlo Matera; Sara Caldas-Martínez; Pedro Mateos-Aparicio; Julia F Weinert; Aida Garrido-Charles; Enrique Claro; Maria V Sanchez-Vives; Pau Gorostiza Journal: Adv Sci (Weinh) Date: 2021-05-21 Impact factor: 16.806
Authors: Farfán-García Eunice Dalet; Trujillo-Ferrara José Guadalupe; Castillo-Hernández María Del Carmen; Guerra-Araiza Christian Humberto; Soriano-Ursúa Marvin Antonio Journal: Neural Regen Res Date: 2013-08-25 Impact factor: 5.135